May 13, 2014 10:14 UTC

Research and Markets: Notch Signaling Pathway in Oncology Drug Pipeline 2014: 249 Companies Plus Partners Developing 343 Notch Pathway Targeting Drugs in 1,214 Developmental Projects

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Notch Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.

Aberrant Notch signaling has been linked to a number of malignancies including leukemias, lymphomas and carcinomas of the breast, skin, lung, cervix and kidneys.

There are today 249 companies plus partners developing 343 Notch pathway targeting drugs in 1214 developmental projects in cancer.

In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 197 drugs. Notch Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 209 different targets.

All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 204 out of the 206 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 43 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

  • Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
  • Find competitors, collaborations partners, M&A candidates etc.
  • Jump start competitive drug intelligence operations
  • Excellent starting point for world wide benchmarking
  • Compare portfolio and therapy focus with your peers
  • Speed up pro-active in-/out licensing strategy work
  • Fast and easy way of tracking drugs using search engines

Pipeline Breakdown According to Number of Drugs

  • Marketed # 31
  • Registered # 1
  • Pre-registration # 6
  • Phase III # 37
  • Phase II # 118
  • Phase I # 132
  • Preclinical # 181
  • No Data # 5
  • Suspended # 5
  • Ceased # 197

For more information visit


Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Source: Research and Markets